Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Depotech(depo) -- Ignore unavailable to you. Want to Upgrade?

To: Czechsinthemail who wrote (693)	1/20/1998 10:52:00 AM
From: JCS	Read Replies (1) \| Respond to of 887

Anybody have any comments or insights on the ramifications of these? SAN DIEGO--(BUSINESS WIRE)--Jan. 20, 1998--DepoTech Corp. (NASDAQ:DEPO) today announced that Sinil Kim, M.D., co-founder of the company has resigned as vice president, Advanced Technology and chief scientific officer to pursue other interests. His responsibilities will be assumed by Dr. Sheldon A. Schaffer, DepoTech's vice president, Pharmaceutical Development. The company also announced that Linda J. Paradiso, D.V.M. has resigned as vice president, Clinical Development to pursue other interests, effective Jan. 30, 1998. The company has initiated a search for a replacement. Her current functions, including the management of on-going clinical trials, will be assumed by DepoTech's clinical development group in collaboration with an outside clinical research organization until a successor is found. DepoTech is a drug delivery company dedicated to the development and manufacture of innovative, sustained-release therapeutic products based on DepoFoam(TM) technology. Products are being developed to satisfy medical needs in cancer, pain management and other fields. -0- Note: This release moved over Business Wire Jan. 20, 1998. -0- This press release may contain forward-looking statements regarding DepoTech. Actual results could differ materially from those described in this news release as a result of a number of factors, including, but not limited to the following: There can be no assurance that replacements sought by the company will be found, that any product in the DepoTech product pipeline will be successfully developed or manufactured, or that final results of human clinical trials will be supportive of regulatory approvals required to market products, or that final regulatory approval will be received in a timely manner, if at all, or that patient and physician acceptance of these products will be achieved. The company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this release. Additional written materials and recent releases regarding DepoTech are available on the World Wide Web at depotech.com . DepoFoam is a trademark of DepoTech Corp. CONTACT: DepoTech Corp. Edward L. Erickson, 619/625-2424 KEYWORD: CALIFORNIA BW1114 JAN 20,1998 SAN DIEGO--(BUSINESS WIRE)--Jan. 20, 1998--DepoTech Corp. (NASDAQ:DEPO) today announced that a Marketing Authorization Application has been submitted to the European Medicines Evaluation Agency for its anticancer drug, Savedar(TM) (cytarabine liposome injection). Savedar is an injectable sustained-release formulation of the chemotherapeutic agent, cytarabine, indicated in this application for patients with neoplastic meningitis from solid tumors. Subject to approval, Savedar (U.S. trade name, DepoCyt(TM)) will be marketed in the European Union by Pharmacia & Upjohn. DepoTech is a drug delivery company dedicated to the development and manufacture of innovative, sustained-release therapeutic products based on DepoFoam(TM) technology. Products are being developed to satisfy medical needs in cancer, pain management and other fields. -0- Note: This release moved over Business Wire Jan. 20, 1998. -0- This press release may contain forward-looking statements regarding programs for DepoCyt/Savedar. Actual results could differ materially from those described in this news release as a result of a number of factors, including, but not limited to the following: There can be no assurance that any product in the DepoTech product pipeline will be successfully developed or manufactured, or that final results of human clinical trials will be supportive of regulatory approvals required to market products, or that final regulatory approval will be received in a timely manner, if at all, or that patient and physician acceptance of these products will be achieved. In December 1997, the Oncologic Drugs Advisory Committee to the U.S. Food and Drug Administration declined to recommend approval of DepoCyt for use in patients with neoplastic meningitis from solid tumors. The final decision regarding marketing approval of new therapeutics resides with FDA officials subsequent to any recommendation of the Committee. The company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this release. -0- Additional written materials and recent releases regarding DepoTech are available on the World Wide Web at depotech.com . DepoFoam is a trademark of DepoTech Corp. CONTACT: DepoTech Corp., San Diego Edward L. Erickson, 619/625-2424 or StratiPoint Group Mike Jackman, 415/388-3216 KEYWORD: CALIFORNIA BW1100 JAN 20,1998